Gottlieb Josh, Higley Cory, Sosnowski Roman, Bjurlin Marc A
New York Institute of Technology College of Osteopathic Medicine Old Westbury, NY.
Department of Uro-oncology, M. Sklodowska-Curie Memorial Cancer Center and Institute of Oncology Warsaw, Poland.
Rev Urol. 2016;18(4):194-204. doi: 10.3909/riu0729.
Smoking is a known modifiable risk factor in the development of genitourinary malignancies. Although the association has long been supported by numerous research studies, the impact of smoking cessation on the decreased risk of genitourinary malignancies is less well studied. PubMed databases were searched using the terms smoking, smoking cessation, bladder cancer, kidney cancer, prostate cancer, penile cancer, testicular cancer, their synonyms, and also targeted manual searches to perform a literature review in order to summarize the benefits of cessation on disease progression and patient outcomes including survival and morbidities. Our review yielded substantial evidence highlighting the improved outcomes observed in those diagnosed with bladder, renal, and prostate cancers. The risk of bladder cancer is reduced by up to 60% in those who were able to quit for 25 years and the risk of kidney malignancy was reduced by 50% in those who abstained from smoking for 30 years. A similar trend of reduced risk was observed for prostate cancer with those who quit for more than 10 years, having prostate cancer mortality risks similar to those that never smoked. Although the data were encouraging for bladder, renal, and prostate malignancies, there are comparatively limited data quantifying the benefits of smoking cessation for penile and testicular cancers, highlighting an opportunity for further study. The role of urologists and their impact on their patients' likelihood to quit smoking shows more than half of urologists never discuss smoking cessation upon diagnosis of a malignancy. Most urologists said they did not provide cessation counseling because they do not believe it would alter their patients' disease progression. Studies show urologists have more influence at changing their patients' smoking behaviors than their primary care physicians. The diagnosis of cancer may lead to a teachable moment resulting in increased smoking quit rates. Furthermore, implementing a brief 5-minute clinic counseling session increases quit attempts and quit rates. Diagnosis of genitourinary cancers and the following appointments for treatment provide a unique opportunity for urologists to intervene and affect the progression and outcome of disease.
吸烟是泌尿生殖系统恶性肿瘤发生过程中一个已知的可改变风险因素。尽管这一关联长期以来得到了众多研究的支持,但戒烟对降低泌尿生殖系统恶性肿瘤风险的影响却鲜少被深入研究。我们利用“吸烟”“戒烟”“膀胱癌”“肾癌”“前列腺癌”“阴茎癌”“睾丸癌”及其同义词在PubMed数据库中进行检索,并开展针对性的人工检索以进行文献综述,目的是总结戒烟对疾病进展以及包括生存和发病率在内的患者预后的益处。我们的综述得出了大量证据,凸显了在膀胱癌、肾癌和前列腺癌患者中观察到的改善预后情况。能够戒烟25年的人群患膀胱癌的风险降低多达60%,而戒烟30年的人群患肾恶性肿瘤的风险降低50%。对于前列腺癌,戒烟超过10年的人群也呈现出类似的风险降低趋势,其前列腺癌死亡风险与从不吸烟的人群相似。尽管这些数据对于膀胱癌、肾癌和前列腺癌来说很鼓舞人心,但量化戒烟对阴茎癌和睾丸癌益处的数据相对有限,这凸显了进一步研究的必要性。泌尿外科医生的作用以及他们对患者戒烟可能性的影响表明,超过一半的泌尿外科医生在患者被诊断为恶性肿瘤时从未讨论过戒烟问题。大多数泌尿外科医生表示他们不提供戒烟咨询,因为他们认为这不会改变患者的疾病进展。研究表明,泌尿外科医生在改变患者吸烟行为方面比初级保健医生更具影响力。癌症诊断可能会带来一个可施教的时机,从而提高戒烟率。此外,开展一场简短的5分钟门诊咨询会能增加戒烟尝试和戒烟率。泌尿生殖系统癌症的诊断以及后续的治疗预约为泌尿外科医生提供了一个独特的机会来进行干预并影响疾病的进展和预后。